Genomics of Cancer: a New Era of Cancer Prevention

Collaborative Research on Predicting Prostate Cancer Risks


Say something interesting about your business here.

Artificial Intelligence and Genomics to Predict Cancer Treatment


What's something exciting your business offers? Say it here.

Cancer Treatment


Give customers a reason to do business with you.

Artificial Intelligence and Genomics to Predict Cancer Treatment, QIMR, Max Kelsen, genomiQa

Genomics and AI to Predict Cancer Treatment

Integrating genomics and artificial intelligence to predict treatment responses in cancer patients is going to become a reality. A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. The official announcement is made today by Assistant Minster for Science, Jobs and Innovation, Zed Seselja, and Federal Member for Brisbane, Trevor Evans on 25 Jul 2018. 

BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialised in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner.

The Project will receive $2.6 million under the fifth round of the CRC-P Program, and has attracted $6.4 million of cash and in-kind contributions from industry partners. "This project will firmly establish the role of artificial intelligence and whole genome analysis in the future of precision medicine" said Nicholas Therkelsen-Terry CEO of Max Kelsen.

Colin Albert, CEO of genomiQa, a spin-out company of QIMR Berghofer Institute of Medical Research said the project would help to unlock the value of whole genome data for patients and clinicians. “This project will firmly establish the role of whole genome analysis and artificial intelligence to help predict the response of immunotherapy for the treatment of cancer.” 

Mr Albert said genomiQa’s high-quality genomic pipeline was developed by founders Dr Nic Waddell and Dr. John Pearson.

Dr. Bicheng Yang, Director of BGI Australia said, “BGI is proud to provide sequencing support for this $9.1 million project, which will help establish whole genome sequencing as part of routine clinical practice, as BGI’s objective is to make sequencing more affordable and accessible to benefit the general public”.  More in the News


Collaborative Research on Predicting Prostate Cancer Risks

BGI and Maxwell Plus have executed a collaborative research project “A model to predict risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers” in September. Prostate cancer is the second most common type of cancer among males in Western countries, with an estimated 165,000 new cases and 29,500 cancer deaths in 2018 alone. The objective of the project is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between prevalence of prostate, breast, ovarian and colorectal cancers in the families of patients. The risk of the genetic makeup and family history will be combined into a risk model for predicting advanced or metastatic prostate cancer. All samples will be sequenced on the cutting-edge BGI genetic sequencer, MGISEQ-2000, in the BGI Australia laboratory. Keep reading

About Maxwell Plus

Founded in 2016, Maxwell Plus is a growing Brisbane based medical technology startup rethinking the way we detect and diagnose disease. By combining machine learning with medical imaging the team are working to make cancer diagnosis faster, more affordable and more accurate.

Find out more